MontenegroTuberculosis profile
Population  2015 <1 million
Estimates of TB burden*, 2015 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) <0.01 (<0.01–<0.01) 0.41 (0.38–0.44)
Mortality (HIV+TB only) <0.01 (<0.01–<0.01) 0.05 (0.01–0.1)
Incidence  (includes HIV+TB) 0.13 (0.084–0.19) 21 (13–30)
Incidence (HIV+TB only) <0.01 (<0.01–<0.01) 0.17 (0.11–0.25)
Incidence (MDR/RR-TB)** <0.01 (0–<0.01) 0.5 (0–1.2)
Estimated TB incidence by age and sex (thousands)*, 2015
  0-14 years > 14 years Total
Females 0 (0–<0.01) 0.036 (0.01–0.063) 0.036 (<0.01–0.066)
Males 0.01 (<0.01–0.014) 0.084 (0.059–0.11) 0.094 (0.065–0.12)
Total 0.01 (<0.01–0.013) 0.12 (0.093–0.15) 0.13 (0.084–0.19)
TB case notifications, 2015  
Total cases notified 80
Total new and relapse 80
          - % tested with rapid diagnostics at time of diagnosis  
          - % with known HIV status 91%
          - % pulmonary 96%
          - % bacteriologically confirmed among pulmonary 74%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2015 62% (43–95)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2015 0.02 (0.02–0.04)
TB/HIV care in new and relapse TB patients, 2015 Number (%)
Patients with known HIV-status who are HIV-positive 1 1%
          - on antiretroviral therapy 1 100%
Drug-resistant TB care, 2015 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  1
(0–4)
Estimated % of TB cases with MDR/RR-TB 1.9% (0.05–10) 0% (0–60)  
% notified tested for rifampicin resistance 71% 80% 57
MDR/RR-TB cases tested for resistance to second-line drugs   0
Laboratory-confirmed cases MDR/RR-TB: 1, XDR-TB: 0
Patients started on treatment **** MDR/RR-TB: 1, XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2014 89% 113
Previously treated cases, excluding relapse, registered in 2014   0
HIV-positive TB cases, all types, registered in 2014   0
MDR/RR-TB cases started on second-line treatment in 2013   0
XDR-TB cases started on second-line treatment in 2013   0
TB preventive treatment, 2015  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
 
TB financing, 2016  
National TB budget (US$ millions)  
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2015
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-12-08 Data: www.who.int/tb/data